Strong Price Performance and Market Outperformance
On 13 July 2026, Parmax Pharma’s stock price closed at Rs.93.30, marking a new 52-week and all-time high. The stock opened and traded steadily at this peak price throughout the day, registering a daily gain of 1.99%, significantly outperforming the Sensex, which declined by 0.24% on the same day. Over the past 21 consecutive trading sessions, the stock has delivered an impressive 65.13% return, underscoring sustained buying interest and momentum.
Comparative performance metrics highlight Parmax Pharma’s exceptional run relative to the broader market. The stock’s one-week gain stands at 10.38%, while the Sensex fell by 1.15%. Over one month, Parmax Pharma surged 57.28%, dwarfing the Sensex’s modest 2.46% rise. The three-month performance is even more striking, with the stock appreciating 200.77% compared to the Sensex’s 0.70% gain. Year-to-date, Parmax Pharma has soared 175.79%, while the Sensex has declined 9.20%. Over one year, the stock’s return of 122.14% contrasts with the Sensex’s negative 6.20%.
Longer-term comparisons also reveal strong relative gains. Over three years, Parmax Pharma has risen 221.61%, well ahead of the Sensex’s 18.04% increase. Over five years, the stock’s 75.21% gain surpasses the Sensex’s 46.64% advance. However, the stock has no recorded price movement over ten years, while the Sensex has appreciated 178.20% in the same period.
Technical Indicators Confirm Bullish Momentum
The technical outlook for Parmax Pharma remains robust. The overall trend is classified as bullish, a status that was upgraded on 8 June 2026 when the stock traded at Rs.48.81. Key technical indicators support this positive momentum: the Moving Average Convergence Divergence (MACD), Bollinger Bands, Know Sure Thing (KST), and Dow Theory signals are all bullish on weekly and monthly timeframes. The stock is trading above all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the strength of the uptrend.
Immediate support is established at the 52-week low of Rs.22.60, while the stock has surpassed previous resistance levels at Rs.37.50 (200-day moving average), Rs.41.80 (100-day moving average), and Rs.76.05 (20-day moving average). The current all-time high of Rs.93.30 represents a significant resistance level that the stock has now breached.
Valuation and Financial Metrics
Despite the strong price appreciation, Parmax Pharma remains a loss-making entity, with no reported price-to-earnings (P/E) ratio due to negative earnings. The price-to-book value stands at -5.57x, reflecting the company’s current financial position. Enterprise value multiples such as EV/EBITDA (-12.60x) and EV/EBIT (-9.80x) are also negative, consistent with the company’s loss-making status. The EV/Sales ratio is 3.72x, while EV/Capital Employed is 9.55x.
The company does not currently pay dividends, with dividend yield and payout ratios not applicable. The valuation assessment data is not available, reflecting the challenges in applying traditional valuation metrics to a company with negative earnings.
Quality Assessment Highlights
Parmax Pharma’s overall quality grade is classified as below average, based on long-term financial performance. Key quality factors include a 5-year sales decline of 14.30% and a significant 5-year EBIT contraction of 225.63%. The company maintains a net cash position, with negative net debt to equity of -1.77, and no promoter share pledging, which are positive indicators of financial prudence.
However, average return on capital employed (ROCE) is weak at -28.89%, and average return on equity (ROE) is modest at 5.12%. Management risk and growth metrics are also rated below average. The company’s tax ratio stands at 100%, and it has zero dividend payout, reflecting its current reinvestment or loss absorption phase.
Recent Financial Trends
Short-term financial trends remain negative as of March 2026. The company reported a quarterly earnings per share (EPS) of -₹1.55, the highest in recent quarters, but net profit after tax (PAT) for the nine months stood at -₹3.39 crores, declining by 50.12%. Net sales over the latest six months were ₹7.64 crores, down 31.23%. The debtors turnover ratio was at a low 3.83 times, and profit before tax excluding other income was -₹2.30 crores for the quarter.
Delivery volumes have shown a positive trend, with a 1-month delivery volume increase of 13.23% and a substantial 1-day delivery volume spike of 131.54% compared to the 5-day average, indicating heightened trading activity around the recent price peak.
Summary of the Stock’s Journey to the Peak
Parmax Pharma’s ascent to its all-time high price of Rs.93.30 is the culmination of a sustained rally that began with a bullish trend upgrade in early June 2026. The stock’s consistent outperformance against the Sensex and its sector peers over multiple time horizons highlights a strong market response to its price action. While the company’s financial fundamentals reflect challenges typical of a micro-cap pharmaceutical entity, the stock’s technical strength and trading momentum have propelled it to this significant milestone.
Investors and market participants will note the stock’s ability to maintain gains above key moving averages and its resilience in the face of broader market fluctuations. The absence of promoter pledging and a net cash position provide some financial stability amid the company’s ongoing efforts to improve profitability and operational metrics.
